



Medicines Patent Pool Governance Board Meeting #37

May 23rd – 24th, 2024
In person meeting

Attendees

Governance Board Members:

Marie-Paule Kieny (Chair), Mojisola Christianah Adeyeye, Grégory Bonnaud, Peter Maybarduk, Govindarajan Narayanan, Maximiliano Santa Cruz, Pushpa Vijayaraghavan.

Excused Board Members:

Maureen Luba

Non-voting Members:

Peter Beyer – Expert Advisory Group Chair, Jackson Hungu – Unitaidd Project Team, Amy Dietterich – World Intellectual Property Organisation Representative, Antony Scott Taubman – World Trade Organisation Representative.

Excused Non-voting Members:

Yukiko Nakatani – WHO Representative.

Medicines Patent Pool Foundation Management Team:

Charles Gore – Executive Director, Esteban Burrone – Policy, Strategy and Market Access Director, ELT, Jane Caldwell – Chief Operating Officer, Ruth Foley – Monitoring and Evaluation Manager, Ike James – Technology Transfer Director, ELT, Gelise McCullough – Communications Director, ELT, Sandra Nobre – Business Development and Partnerships Director, ELT, Chan Park – General Counsel, Gosha Stehle – HR Manager, Agnese Tonnina – Senior Manager, Grants and Governance, Carmen Turnbull – Senior Accounting Manager.

Summary of Decisions

The Governance Board of the Medicines Patent Pool:

1. Requested the Management to initiate the process to establish a repository of geographically diverse pre-selected manufacturers for both pandemic and routine products to be updated periodically with a view to shortening timelines for the selection of licensees, pending availability of the necessary funds. In the case of pandemic, an EOI will be opened both to pre-selected and other manufacturers.
2. Agreed to expand the range of regulatory authorities that can be included in MPP's licences for quality assurance purposes to encompass regulatory authorities of countries that have been designated as WHO-Listed Authorities (WLAs) in the relevant product stream and function. In addition, in exceptional circumstances, when an SRA approved product cannot be used in LMICs, and certain modifications are required, the Board requested MPP to explore, in discussions with the relevant licensor(s), the possibility of relying on assessments from a recognised procurement agency that is in compliance with the Model Quality Assurance System for Procurement Agencies (MQAS) for quality assurance purposes.
3. Approved the 2023 financial statements, auditors' report, and 2023 annual report.
4. Approved the appointment of Deloitte & Touche as MPP's auditors for a three-year term.
5. Approved the 2024 budget re-forecast.
6. Approved the Key Organisational Indicators (KOI) results report for 2023.
7. Approved the proposed Menstrual and menopause policy.
8. Unanimously agreed to invite Board Member Pushpagiri Vijayaraghavan to serve for a second three-year term of office starting on September 1st, 2024 until August 31st, 2027.
9. Approved the appointment of Dr Martin Friede as EAG Expert in Science and Research and Development in Vaccines and Biologics.